A molecular hybrid comprising AS1411 and PDGF-BB aptamer, cholesterol, and doxorubicin for inhibiting proliferation of SW480 cells,Journal of Molecular Recognition

当前位置： X-MOL 学术 › J. Mol. Recognit. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

A molecular hybrid comprising AS1411 and PDGF-BB aptamer, cholesterol, and doxorubicin for inhibiting proliferation of SW480 cells
Journal of Molecular Recognition ( IF 2.3 ) Pub Date : 2021-07-13 , DOI: 10.1002/jmr.2926
Pichayanoot Rotkrua ₁ , Walaiporn Lohlamoh ₁ , Paphada Watcharapo ₂ , Boonchoy Soontornworajit ₂

Affiliation

Cancer treatment commonly relies on chemotherapy. This treatment faces many challenges, including treatment specificity and undesired side effects. To address these, a Dox-loaded Chol–aptamer molecular hybrid (Dox-CAH) was developed. This multivalent interaction system combines the key function of each integrated species: doxorubicin, cholesterol, and two aptamers binding to nucleolin and platelet-derived growth factor BB (PDGF-BB). The study has four stages: preparation of CAH via oligonucleotide hybridization, intercalation of doxorubicin into CAH, verification of CAH binding on SW480 by fluorescence microscopy and flow cytometry, and investigation of effect of Dox-CAH on SW480 proliferation. CAH was successfully prepared, as confirmed by electrophoresis. Flow cytometry and fluorescence microscopy demonstrated CAH binding to SW480, due to the presence of the AS1411 aptamer. This molecular hybrid exhibited specific binding because it did not bind to CCD 841 CoN. CAH binding to PDGF-BB compromises its function, as shown by enzyme-linked immunosorbent assay (ELISA) and cell assay. The DNA duplex in this molecular hybrid reduces the cytotoxicity of the Dox-CAH. Binding and the reduction of Dox-CAH toxicity may improve treatment specificity and minimize side effects. Dox-CAH is a model for more effective anticancer therapy, allowing incorporation of chemotherapeutic drugs and recognition elements.

中文翻译：

一种包含 AS1411 和 PDGF-BB 适体、胆固醇和多柔比星的分子杂交体，用于抑制 SW480 细胞的增殖

癌症治疗通常依赖于化疗。这种治疗面临许多挑战，包括治疗特异性和不良副作用。为了解决这些问题，开发了一种载有 Dox 的 Chol-适体分子杂化物 (Dox-CAH)。这种多价相互作用系统结合了每个整合物种的关键功能：多柔比星、胆固醇和与核仁素和血小板衍生生长因子 BB (PDGF-BB) 结合的两个适体。该研究分为四个阶段：通过寡核苷酸杂交制备CAH，将阿霉素嵌入CAH，通过荧光显微镜和流式细胞术验证CAH与SW480的结合，以及研究Dox-CAH对SW480增殖的影响。经电泳证实，CAH 制备成功。流式细胞术和荧光显微镜显示 CAH 与 SW480 结合，由于存在 AS1411 适体。这种分子杂合体表现出特异性结合，因为它不与 CCD 841 CoN 结合。如酶联免疫吸附试验 (ELISA) 和细胞试验所示，CAH 与 PDGF-BB 的结合损害了其功能。这种分子杂交体中的 DNA 双链体降低了 Dox-CAH 的细胞毒性。结合和降低 Dox-CAH 毒性可以提高治疗特异性并最大限度地减少副作用。Dox-CAH 是一种更有效的抗癌治疗模型，允许结合化疗药物和识别元件。这种分子杂交体中的 DNA 双链体降低了 Dox-CAH 的细胞毒性。结合和降低 Dox-CAH 毒性可以提高治疗特异性并最大限度地减少副作用。Dox-CAH 是一种更有效的抗癌治疗模型，允许结合化疗药物和识别元件。这种分子杂交体中的 DNA 双链体降低了 Dox-CAH 的细胞毒性。结合和降低 Dox-CAH 毒性可以提高治疗特异性并最大限度地减少副作用。Dox-CAH 是一种更有效的抗癌治疗模型，允许结合化疗药物和识别元件。

更新日期：2021-07-13

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11